Is Abbott building the next integrated platform for complex heart rhythm treatment?
Abbott has PFA momentum, but rhythm care is becoming a platform battle. Can clinical data turn into durable adoption?
Can CARTOSOUND SONATA help Johnson & Johnson tighten its grip on electrophysiology workflow?
See how Johnson & Johnson is using CARTOSOUND SONATA and VARIPULSE to reshape electrophysiology workflow and arrhythmia care. Read more.
Johnson & Johnson expands pulsed field ablation footprint as VARIPULSE reaches Peru electrophysiology centers
Johnson & Johnson launches VARIPULSE pulsed field ablation technology in Peru. Discover what this means for atrial fibrillation treatment and electrophysiology innovation.
Johnson & Johnson’s early OMNYPULSE data show promise, but the real test lies ahead
Johnson & Johnson has presented 12-month pilot data from the OMNY-AF study evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation at the 2026 AF Symposium. The early pilot cohort reported high acute procedural success, no procedure-related adverse events, and a 12-month freedom from atrial fibrillation rate approaching 90 percent. The […]
Medtronic expands Affera platform with Sphere-360 catheter CE Mark and IDE trial kickoff
Medtronic’s Sphere-360 catheter earns CE Mark and begins U.S. IDE trial. Find out what this means for the future of pulsed field ablation.